[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anorectal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anorectal-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100567544","phase-2-lenvatinib-and-pembrolizumab-to-treat-patients-with-anal-or-rectum-cancer-that-has-gotten-worse-after-initial-treatment-100567544",false,"NCT06669572","Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment","A Phase II, Multi-center, Single Arm Trial of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Locally Advanced and\u002For Metastatic Anorectal Squamous Cell Carcinoma (ASCC) After Progression on First Line Chemotherapy.","Inclusion Criteria:\n\n* Histological confirmation of anorectal squamous cell carcinoma per the American Joint Committee on Cancer 8th edition. NOTE: If archived tissue is not available for diagnostic histological confirmation \\[core, incisional, or excisional\\], a new biopsy of a tumor lesion prior to tumor irradiation should be obtained.\n* Unresectable locally advanced or metastatic anorectal squamous cell carcinoma following progression on first line chemotherapy or chemoradiation therapy. Prior use of immunotherapy with Retifanlimab is allowed but not mandatory.\n* Prior chemoradiation therapy with either definitive intent or palliative intent is allowed.\n* Measurable disease based on Response Evaluation Criteria In Solid Tumors 1.1 Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions within 28 days prior to registration.\n\nExclusion Criteria:\n\n* Has received prior therapy with an anti-PD-1, anti- PDL1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T cell receptor (eg, CTLA-4, OX-40, CD137) with the exception of Retifanlimab immunotherapy.\n* Prior significant immunotherapy related adverse events requiring permanent discontinuation of the immunotherapy agents including events like pneumonitis, myocarditis, renal failure, Guillain Barre syndrome or myasthenia gravis.\n* Active autoimmune disease with ongoing treatment with chronic immunosuppressive therapy such as DMARDs .","ALL","18 Years",{"count":19,"type":20},35,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to gather information on the safety and effectiveness of lenvatinib combined with pembrolizumab in anal\u002Frectal cancer that has spread to other parts of the body and will not respond to standard care.",[26,27],"Carcinoma, Squamous Cell","Anorectal Cancer",[29,30,31,32],"chemotherapy","anorectal cancer","Lenvatinib","Pembrolizumab","RECRUITING","2026-04-13",{"date":36,"type":37},"2026-04-15","ACTUAL",{"date":39,"type":37},"2025-07-11",{"date":41,"type":20},"2029-03-26",{"name":43,"class":44},"University of Chicago","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":45},"100609582","vaginal-dilator-therapy-after-pelvic-radiation-100609582","NCT07216456","Vaginal Dilator Therapy After Pelvic Radiation","Improving Engagement With Vaginal Dilator Therapy After Pelvic Radiation: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* female sex\n* adults aged 18 years or older\n* diagnosed with cancer of the anus, anal canal, anorectum, cervix, uterus, vagina, vulva, and\u002For bladder\n* completed pelvic radiation therapy in the past year\n* dilator therapy recommended by medical provider and standardized dilator received from provider\n* able to speak\u002Fread English\n\nExclusion Criteria:\n\n* aged less than 17 years\n* under the care of a pelvic floor physical therapist at the time of study enrollment\n* have a major\u002Fserious psychiatric concern (e.g., schizophrenia) as indicated by medical chart\u002Fmedical provider\n* inability to provide consent","FEMALE",{"count":55,"type":20},88,[57],"NA","This study is testing a new program to help women who have had pelvic radiation therapy to use vaginal dilators more regularly. Vaginal dilators are important tools that can help prevent or treat vaginal narrowing (called vaginal stenosis), which can happen after radiation and make medical exams or sexual activity painful or difficult. Even though dilators are recommended, many women don't use them as often as needed.\n\nIn this study, 88 participants will be randomly assigned to one of two groups:\n\n* One group will receive the new behavioral program, which includes support and strategies to help with regular dilator use.\n* The other group will receive written educational materials (enhanced usual care).\n\nThe study will look at how often and how long participants use their dilators, and whether the program helps reduce symptoms like pain or emotional distress. Participants will complete surveys at the beginning of the study and again at 3, 6, and 9 months, plus short monthly check-ins.\n\nThe goal is to see if the program is helpful and easy to use, and to prepare for a larger study in the future.",[60,61,62,63,27,64],"Pelvic Radiotherapy","Vaginal Stenosis","Pelvic Cancer","Gynecologic Cancers","Urologic Cancer",[66,67],"vaginal dilator therapy","pelvic radiation","NOT_YET_RECRUITING","2025-10-13",{"date":71,"type":37},"2025-10-15",{"date":73,"type":20},"2027-08-01",{"date":75,"type":20},"2030-04-30",{"name":77,"class":44},"Duke University"]